Treating Patients With BRAF V600E Mutation and Advanced RAI-Refractory DTC

Opinion
Video

An expert on thyroid cancer provides insights on treating patients with advanced RAI-refractory DTC who harbor BRAFV600E mutations.

Case: A 64-Year-Old Woman with DTC

Initial presentation

  • A 64-year-old woman presents with a painless “lump on her neck” with occasional swelling. She states she noticed this just a few days after returning from vacation.
  • PMH: Hyperlipidemia managed with medication; COPD
  • PE: palpable, non-tender solitary right-of-the midline neck mass; mobile supraclavicular mass on the same side; otherwise unremarkable


Clinical workup and initial treatment

  • Labs: TSH WNL
  • Ultrasound of the neck revealed a 3.3-cm suspicious right mass in the lobe of the thyroid; 2 suspicious supraclavicular lymph nodes (LNs), largest 2.0 cm in size.
  • Ultrasound-guided FNAB of the thyroid mass and the largest LN confirmed papillary thyroid carcinoma.
  • Patient underwent total thyroidectomy with central compartment node dissection and right selective neck dissection.
    • Pathology: 3.0-cm papillary thyroid cancer, columnar cell variant; 4/14 lateral positive LN, 3/3 central positive LN​
    • Largest lateral node was 2.2 cm with no extra-nodal extension
    • Margins were negative
    • Microscopic extrathyroidal extension present
  • Probable stage II; T2N1bM0 papillary thyroid cancer


Subsequent treatment and follow-up

  • She was treated with radioactive iodine 150 millicuries
    • Whole body scan showed uptake in the neck, consistent with remnant thyroid tissue
  • She was started on levothyroxine suppression therapy
  • Follow-up at 6 months
    • TSH 0.1 µU/mL, thyroglobulin 24 ng/mL (negative anti-thyroglobulin antibodies)
    • Chest CT scan showed 8 small bilateral lung nodules only several mm in size
  • Next-generation sequencing was negative for mutations, rearrangements
  • Follow-up CT chest scan and blood tests 3 months later
    • Thyroglobulin increased
    • Lung nodules had increased by up to 1 cm in size
  • Lenvatinib 24mg po qd was initiated

This is a video synopsis/summary of a Case-Based Peer Perspective featuring: Lori Wirth, MD.

Wirth discusses her treatment approach for patients with BRAF V600E mutation–positive, radioactive iodine (RAI)–refractory papillary thyroid cancer (PTC). She uses lenvatinib as her first-line drug of choice based on the SELECT trial results, which showed that patients with BRAF V600E mutations benefited from lenvatinib treatment in terms of response rate and progression-free survival (PFS), similar to patients with BRAF wild-type disease.

A multicenter National Comprehensive Cancer Network phase 2 trial investigated dabrafenib with or without trametinib in patients with BRAF V600E mutation–positive, RAI-refractory PTC. The objective response rates were 30% to 35%, and the PFS ranged from 10.7 to 15.1 months. Although a direct comparison cannot be made, the results do not appear as robust as those seen with front-line lenvatinib.

An ongoing international phase 3 trial is investigating dabrafenib plus trametinib compared with best supportive care in patients with second-line progressive BRAF V600E mutation–positive PTC. Wirth thinks this trial will provide important data on the effectiveness of dabrafenib and trametinib in the second-line setting. Based on the FDA approval for dabrafenib and trametinib as tissue-agnostic therapy in patients with BRAF mutation–positive solid tumors without alternative options, using these agents in the second line is a reasonable approach if clinical trial enrollment is not available.

Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.

Recent Videos
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Solly Chedid, MD, an expert on MDS
Related Content